Literature DB >> 10775598

Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.

S Sei1, Q E Yang, D O'Neill, K Yoshimura, K Nagashima, H Mitsuya.   

Abstract

Although the full sequence of the human immunodeficiency virus type 1 (HIV-1) genome has been known for more than a decade, effective genetic antivirals have yet to be developed. Here we show that, of 22 regions examined, one highly conserved sequence (ACTCTTTGGCAACGA) near the 3' end of the HIV-1 gag-pol transframe region, encoding viral protease residues 4 to 8 and a C-terminal Vpr-binding motif of p6(Gag) protein in two different reading frames, can be successfully targeted by an antisense peptide nucleic acid oligomer named PNA(PR2). A disrupted translation of gag-pol mRNA induced at the PNA(PR2)-annealing site resulted in a decreased synthesis of Pr160(Gag-Pol) polyprotein, hence the viral protease, a predominant expression of Pr55(Gag) devoid of a fully functional p6(Gag) protein, and the excessive intracellular cleavage of Gag precursor proteins, hindering the processes of virion assembly. Treatment with PNA(PR2) abolished virion production by up to 99% in chronically HIV-1-infected H9 cells and in peripheral blood mononuclear cells infected with clinical HIV-1 isolates with the multidrug-resistant phenotype. This particular segment of the gag-pol transframe gene appears to offer a distinctive advantage over other regions in invading viral structural genes and restraining HIV-1 replication in infected cells and may potentially be exploited as a novel antiviral genetic target.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10775598      PMCID: PMC111982          DOI: 10.1128/jvi.74.10.4621-4633.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  152 in total

1.  Phospholipid membrane permeability of peptide nucleic acid.

Authors:  P Wittung; J Kajanus; K Edwards; P Nielsen; B Nordén; B G Malmström
Journal:  FEBS Lett       Date:  1995-05-22       Impact factor: 4.124

2.  p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.

Authors:  M Huang; J M Orenstein; M A Martin; E O Freed
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

3.  A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.

Authors:  Y L Lu; R P Bennett; J W Wills; R Gorelick; L Ratner
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

4.  Incorporation of Vpr into human immunodeficiency virus type 1: role of conserved regions within the P6 domain of Pr55gag.

Authors:  F Checroune; X J Yao; H G Göttlinger; D Bergeron; E A Cohen
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-09-01

5.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

Authors:  D J Kempf; K C Marsh; J F Denissen; E McDonald; S Vasavanonda; C A Flentge; B E Green; L Fino; C H Park; X P Kong
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

6.  Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.

Authors:  E Kojima; T Shirasaka; B D Anderson; S Chokekijchai; S M Steinberg; S Broder; R Yarchoan; H Mitsuya
Journal:  J Infect Dis       Date:  1995-05       Impact factor: 5.226

7.  Antitat gene therapy: a candidate for late-stage AIDS patients.

Authors:  J Lisziewicz; D Sun; A Lisziewicz; R C Gallo
Journal:  Gene Ther       Date:  1995-05       Impact factor: 5.250

8.  Characterization of deletion mutations in the capsid region of human immunodeficiency virus type 1 that affect particle formation and Gag-Pol precursor incorporation.

Authors:  N Srinivasakumar; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers.

Authors:  M A Bonham; S Brown; A L Boyd; P H Brown; D A Bruckenstein; J C Hanvey; S A Thomson; A Pipe; F Hassman; J E Bisi
Journal:  Nucleic Acids Res       Date:  1995-04-11       Impact factor: 16.971

10.  In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.

Authors:  J A Partaledis; K Yamaguchi; M Tisdale; E E Blair; C Falcione; B Maschera; R E Myers; S Pazhanisamy; O Futer; A B Cullinan
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more
  9 in total

1.  Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production.

Authors:  Neerja Kaushik; Amartya Basu; Paul Palumbo; Rene L Myers; Virendra N Pandey
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.

Authors:  S Peters; M Muñoz; S Yerly; V Sanchez-Merino; C Lopez-Galindez; L Perrin; B Larder; D Cmarko; S Fakan; P Meylan; A Telenti
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

3.  Inhibition of human immunodeficiency virus replication by cell membrane-crossing oligomers.

Authors:  Wilfried Posch; Stefan Piper; Thomas Lindhorst; Birgit Werner; Adam Fletcher; Holger Bock; Cornelia Lass-Flörl; Heribert Stoiber; Doris Wilflingseder
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

4.  Design of embedded chimeric peptide nucleic acids that efficiently enter and accurately reactivate gene expression in vivo.

Authors:  Joy Chen; Kenneth R Peterson; Camelia Iancu-Rubin; James J Bieker
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-13       Impact factor: 11.205

5.  Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.

Authors:  Quan-En Yang; Andrew G Stephen; Joseph W Adelsberger; Paula E Roberts; Weimin Zhu; Michael J Currens; Yaxiong Feng; Bruce J Crise; Robert J Gorelick; Alan R Rein; Robert J Fisher; Robert H Shoemaker; Shizuko Sei
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 6.  Prospects for antisense peptide nucleic acid (PNA) therapies for HIV.

Authors:  Virendra N Pandey; Alok Upadhyay; Binay Chaubey
Journal:  Expert Opin Biol Ther       Date:  2009-08       Impact factor: 4.388

7.  Potent antiviral activity of north-methanocarbathymidine against Kaposi's sarcoma-associated herpesvirus.

Authors:  Weimin Zhu; Angela Burnette; Dorjbal Dorjsuren; Paula E Roberts; Mahmoud Huleihel; Robert H Shoemaker; Victor E Marquez; Riad Agbaria; Shizuko Sei
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.938

8.  HIV protein sequence hotspots for crosstalk with host hub proteins.

Authors:  Mahdi Sarmady; William Dampier; Aydin Tozeren
Journal:  PLoS One       Date:  2011-08-15       Impact factor: 3.240

9.  Molecular characterization of the HIV-1 gag nucleocapsid gene associated with vertical transmission.

Authors:  Brian P Wellensiek; Vasudha Sundaravaradan; Rajesh Ramakrishnan; Nafees Ahmad
Journal:  Retrovirology       Date:  2006-04-06       Impact factor: 4.602

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.